Business Wire | Sep 9, 2020 09:00AM EDT

Geron to Present at the H.C. Wainwright Global Investment Conference

Sep. 09, 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 09, 2020--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday, September 14, 2020 at 2:30 p.m. ET.

A live audio webcast of the presentation will be available on Geron's website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company's website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005329/en/

CONTACT: Suzanne Messere Investor and Media Relations investor@geron.com media@geron.com